Select a community
HIV
Find out more about the PatientsLikeMe
HIV Community
Home > Community Treatment Reports > Ativan (lorazepam) Treatment Report
What is Ativan?

Ativan is a brand name for lorazepam, a benzodiazepine, used in the treatment of anxiety disorders. It is used intravenously for status epilepticus. Off label it is used for alcohol detoxification; insomnia; partial complex seizures; agitation; and as an adjunct in antiemetic treatment.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Anxiety 4 1
Other 1 0
Support another treatment 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
1 100%
Moderate
0 0%
Mild
0 0%
None
0 0%

Most commonly reported side effects

Loss of appetite
1 100%
Drowsiness
1 100%
Dizziness
1 100%
Emotional issues
1 100%
Anxiety
1 100%
Paranoid
1 100%
  • Mild
  • Moderate
  • Severe

Dosages

  0.5mg as needed 0.75 mg daily 2 mg daily
  2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Ativan (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe
1 50% Side effects too severe: 50%
Other
1 50% Other: 50%

See all 2 patients who’ve stopped taking Ativan

Currently Taking Ativan

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
1
0
2

Stopped Taking Ativan

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
2
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
1 100%
Somewhat
0 0%
A little
0 0%
Not at all
0 0%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.